Chiral chem license, from one of SEPR's main consultants:
Friday, May 25, 2007
Japanese company licenses Harvard tech
Harvard University signed a licensing agreement that will provide a Japanese company with a technology that is expected to result in more efficient drug manufacturing.
The agreement is between Harvard's Office of Technology Development, whose mission is to make the fruits of Harvard research more accessible to outsiders, and Daiso Co. Ltd.
One challenge faced by pharmaceutical companies is ensuring the proper molecular conformation, or chirality, of manufactured drugs; a hydrolytic kinetic resolution, or HKR, discovered by Harvard chemistry professor Eric Jacobsen, addresses that issue, Harvard said.
Under the agreement, patented HKR technology will be licensed to Daiso, which will use it to synthesize and sell chiral compounds to its drug-manufacturing customers, Harvard said.
Financial details of the agreement were not disclosed.
(By Chris Reidy, Globe staff) |
